Advertisement
Advertisement
U.S. Markets open in 32 mins
Advertisement
Advertisement
Advertisement
Advertisement

Genetic Technologies Limited (GTG.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.0040+0.0010 (+33.33%)
At close: 04:44PM AEDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0040
Open0.0030
Bid0.0030 x 0
Ask0.0040 x 0
Day's Range0.0030 - 0.0040
52 Week Range0.0030 - 0.0090
Volume404,055
Avg. Volume3,702,628
Market Cap27.702M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-0.0010
Earnings DateAug 30, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer

    MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the recent publication of a paper in the Journal of Precision Medicine authored by GTG science team members, Dr Erika Spaeth, Director of Clinical Affairs, Dr Richard Allman, Chief Scientific Officer, and Dr Gillian Dite, Senior Biostatistician. Publication highlig

  • GlobeNewswire

    Genetic Technologies Provides Update on US Operations and Payer Engagement

    MELBOURNE, Australia, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”, “GENE”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, is pleased to report excellent commercial progress in the USA strategic operations with the following updates: Strategic Highlights: Active engagement with 11 US payer groups with an initial target list of 30 with coverage in tens of millions of livesEngagement wi

  • GlobeNewswire

    GENE Momentum building - a year in review

    MELBOURNE, Australia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2022. It has been an exciting 12 months focused on our commercialisation journey. We now have the most comprehensive portfolio of genetic based tests available for individuals and animals. In addition to our p

Advertisement
Advertisement